Breast Cancer

Latest Headlines

Latest Headlines

Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%

Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.

NICE raises ire of breast cancer patients with rejection of Roche's Kadcyla

The National Institute for Health and Care Excellence has issued its final draft guidance for Kadcyla, which declares the drug is too expensive to cover.

Cancer researchers tap computers to support preclinical go/no-go decisions

Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.

AZ's Zoladex could stave off early menopause in breast cancer patients

Now that the Pfizer takeover AstraZeneca fought to avoid is on the rocks--at least for the time being--the pressure's on the British drugmaker to deliver strong growth on its own. And while much of the attention is focused on its pipeline, leading cancer drug Zoladex may be able to chip in, too, with new data suggesting it could help prevent infertility in some breast cancer patients receiving chemo.

GSK misses survival endpoint with Tykerb-Herceptin pairing

Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve  disease-free survival in HER2-positive early breast cancer patients over  Herceptin on its own.

Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments

It will allow doctors to spot patients who will benefit from those treatments.

Experts tip bioinformatics collaborations to improve breast cancer care

The growing pool of genomics data and bioinformatics capabilities present new opportunities to improve outcomes for cancer patients. Yet without coordinated, multidisciplinary collaborations, the industry risks failing to take full advantage, researchers warned this week.

Roche's Perjeta nabs speedy FDA nod in early breast cancer

Perjeta is now the first cancer drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive breast cancer, Perjeta can now reach a huge new group of patients at early stages of the disease.

FDA panel gives 'historic' thumbs-up to Roche's Perjeta in early breast cancer

You might call Perjeta a guinea pig. The new breast cancer drug from Roche's Genentech unit could soon become the first approved for cancer patients before they've had surgery. It would also be the first approved under new FDA guidelines for speeding cancer drugs to patients with early-stage disease.

FDA reviewers back Roche's Perjeta in early breast cancer

Roche's study looked at Perjeta in combination with Roche's Herceptin and chemotherapy, compared with Herceptin and chemo alone. Patients on Perjeta and Herceptin saw statistically significant improvements in tumor size compared with those in the Herceptin-only arm, the FDA reveiewers noted.